Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
CONTEXT: In surveys based on data available prior to 2000, clinical trials funded by for-profit organizations appeared more likely to report positive findings than those funded by not-for-profit organizations. Whether this situation has changed over the past 5 years or whether similar effects are present among jointly funded trials is unknown. OBJECTIVE: To determine in contemporary randomized cardiovascular trials the association between funding source and the likelihood of reporting positive findings. DESIGN: We reviewed 324 consecutive superiority trials of cardiovascular medicine published between January 1, 2000, and July 30, 2005, in JAMA, The Lancet, and the New England Journal of Medicine. MAIN OUTCOME MEASURE: The proportion of trials favoring newer treatments over the standard of care was evaluated by funding source. RESULTS: Of the 324 superiority trials, 21 cited no funding source. Of the 104 trials funded solely by not-for-profit organizations, 51 (49%) reported evidence significantly favoring newer treatments over the standard of care, whereas 53 (51%) did not (P = .80). By contrast, 92 (67.2%) of 137 trials funded solely by for-profit organizations favored newer treatments over standard of care (P<.001). Among 62 jointly funded trials, 35 (56.5%), an intermediate proportion, favored newer treatments. For 205 randomized trials evaluating drugs, the proportions favoring newer treatments were 39.5%, not-for-profit; 54.4%, jointly funded; and 65.5%, for-profit trials (P for trend across groups = .002). For the 39 randomized trials evaluating cardiovascular devices, the proportions favoring newer treatments were 50.0%, not-for-profit; 69.2%, jointly funded; and 82.4%, for-profit trials (P for trend across groups = .07). Regardless of funding source, trials using surrogate end points, such as quantitative angiography, intravascular ultrasound, plasma biomarkers, and functional measures were more likely to report positive findings (67%) than trials using clinical end points (54.1%; P = .02). CONCLUSIONS: Recent cardiovascular trials funded by for-profit organizations are more likely to report positive findings than trials funded by not-for-profit organizations, as are trials using surrogate rather than clinical end points. Trials jointly funded by not-for-profit and for-profit organizations appear to report positive findings at a rate approximately midway between rates observed in trials supported solely by one or the other of these entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Ohn, D, R., Utherford, Homas, G., C., Ole, J, M., Alcolm, O., A., & Rnold (2000) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-199701000-00013 · Cited by 2,026
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Self-citationChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 2×
“Previous attempts to explain this phenomenon have focused largely on design bias, interpretation bias, data suppression, and differential data quality.(5-7,10,11,24) However, with regard to trial design bias, the direction of effect is not always predictable.”
BackgroundScope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 1×
“If confirmed in other areas of investigation, this observation could have implications for the design and conduct of jointly funded projects for which the primary intent is to share costs of pivotal trials with industry partners.(9,16,17) Finally, we believe our observations of differential rates of positive trial rep…”
BackgroundAlbert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,641
Self-citationLee, I.-M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.56 · Cited by 1,137
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationUneasy alliance—clinical investigators and the pharmaceutical industry
Bodenheimer, T. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422024 · Cited by 765 · cited 1×
“If confirmed in other areas of investigation, this observation could have implications for the design and conduct of jointly funded projects for which the primary intent is to share costs of pivotal trials with industry partners.(9,16,17) Finally, we believe our observations of differential rates of positive trial rep…”
BackgroundAls-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746 · cited 2×
“We are aware of data from 1 study of noncardiovascular trials that also found a similar result.(7) If confirmed in other areas of investigation, this observation could have implications for the design and conduct of jointly funded projects for which the primary intent is to share costs of pivotal trials with industry…”
ResultTopol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F.-J., Stone, G. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442502 · Cited by 677
Bhandari, M., Busse, J. W., Jackowski, D., Montori, V. M., Schünemann, H. J., Sprague, S., Mears, D., Schemitsch, E. H., Heels-Ansdell, D., & Devereaux, P. J. (2004) · Europe PMC (PubMed Central) · Cited by 551
Sever, P. S., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 524
The uncertainty principle and industry-sponsored research
Djulbegovic, B., Lacevic, M., Cantor, A., Fields, K. K., Bennett, C. L., Adams, J. R., Kuderer, N. M., & Lyman, G. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02605-2 · Cited by 482
Kjaergard, L., & Als-Nielsen, B. (2002) · BMJ · doi:10.1136/bmj.325.7358.249 · Cited by 433
Clinical trial registration: a statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17034-7 · Cited by 408
Pantoja, T., & Letelier, L. M. (2003) · Revista médica de Chile · doi:10.4067/s0034-98872003001000017 · Cited by 386
Trial Registration at ClinicalTrials.gov between May and October 2005
Zarin, D. A., Tse, T., & Ide, N. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa053234 · Cited by 291
Rochon, P. A. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.2.157 · Cited by 274
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00109 · Cited by 264
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
LaRosa, J. C., Grundy, S. M., & Waters, D. D. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.10.023 · Cited by 163
Fair Conduct and Fair Reporting of Clinical Trials
Rennie, D. (1999) · JAMA · doi:10.1001/jama.282.18.1766 · Cited by 158
Curfman, G. D., Morrissey, S., & Drazen, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejme058314 · Cited by 158
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.024 · Cited by 151
Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development
Fries, J. F., & Krishnan, E. (2004) · Arthritis Res Ther · doi:10.1186/ar1170 · Cited by 142
Industry-sponsored clinical research: a double-edged sword
Montaner, J. S. G., O’Shaughnessy, M. V., & Schechter, M. T. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06891-x · Cited by 137
Randomized clinical trials in Hepatology: Predictors of quality
Kjaergard, L. L., Nikolova, D., & Gluud, C. (1999) · Hepatology · doi:10.1002/hep.510300510 · Cited by 119
Miller, P. B. W., & Weijer, C. (2003) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2003.0014 · Cited by 114
Albert, M. A., Danielson, E., Rifai, N., & Ridker, P. M. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00461-5 · Cited by 110
Self-citationKennedy, L., & Leahy, J. L. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70267-1 · Cited by 102
Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia
Milani, R. V., Ries, A. L., & MYERS, J. N. (1996) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-199603000-00012 · Cited by 92
COMMUNITY‐EQUIPOISE AND THE ETHICS OF RANDOMIZED CLINICAL TRIALS
Gifford, F. (1995) · Bioethics · doi:10.1111/j.1467-8519.1995.tb00306.x · Cited by 89
the Heart Protection Study Collaborative Group (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00911-x · Cited by 89
Edwards, R., & Bhopal, R. (1999) · PubMed · doi:10.25405/ncl.34642230 · Cited by 64
Equipoise and the Ethics of Clinical Research
Freedman, B. (2017) · Research Ethics · doi:10.4324/9781315244426-17 · Cited by 59
Sever, P. S., Dahlöf, B., & Poulter, N. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00278-2 · Cited by 58
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
(2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000165831.51904.01 · Cited by 50
Loehrer, P. J. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70418-8 · Cited by 38
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism*
(2003) · Obstetrics and Gynecology · doi:10.1097/00006250-200307000-00041 · Cited by 16
Frishman, W. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70241-4 · Cited by 5
Community-Equipoise and the Ethics of Randomized Clinical Trials
Gifford, F. (2017) · Routledge eBooks · doi:10.4324/9781315244426-18 · Cited by 4
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Industry sponsorship and research outcome
Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub2 · Cited by 605
Acid-suppressive medication use and the risk for hospital-acquired pneumonia
Herzig, S. J. (2009) · JAMA · doi:10.1001/jama.2009.722 · Cited by 486
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Metadata
- Authors
- Ridker, P. M., & Torres, J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-05-17
- Volume
- 295
- Issue
- 19
- Pages
- 2270
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1999175005
- Cited by
- 303
- References
- 57
- FWCI
- 26.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.